share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
SEC announcement ·  03/21 16:08
Moomoo AI 已提取核心訊息
Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.
Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.
外國私人發行人紅山生物製藥有限公司在2024年3月21日舉行的特別股東大會上成功通過了一項增加其法定股本的決議。如向美國證券交易委員會提交的6-K表格所述，該決議已獲得公司股東的批准。該公司訴訟現已通過引用方式納入公司關於S-8和F-3表格的各種註冊聲明，這些聲明先前已在2013年5月2日至2023年10月13日的指定日期向美國證券交易委員會提交。6-K表格是一份法律文件，通過及時提供重大公司活動的最新信息，確保公司遵守美國證券交易委員會的法規。
外國私人發行人紅山生物製藥有限公司在2024年3月21日舉行的特別股東大會上成功通過了一項增加其法定股本的決議。如向美國證券交易委員會提交的6-K表格所述，該決議已獲得公司股東的批准。該公司訴訟現已通過引用方式納入公司關於S-8和F-3表格的各種註冊聲明，這些聲明先前已在2013年5月2日至2023年10月13日的指定日期向美國證券交易委員會提交。6-K表格是一份法律文件，通過及時提供重大公司活動的最新信息，確保公司遵守美國證券交易委員會的法規。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息